-
UBS: Biotech Will Continue To Outperform In 2015
Tuesday, September 8, 2015 - 1:22pm | 379Read More...In a new report, UBS analyst Matthew Roden discusses the firm’s bullish outlook for biotech stocks. Biotech has had a strong run so far this year, but Roden still sees gas in the tank for several names. Three Drivers UBS sees three drivers for biotech outperformance in the second half...
-
Puma Biotechnology Soars On Phase III Data; Analyst Smells Takeover Candidate
Wednesday, July 23, 2014 - 11:51am | 224Read More...Puma Biotechnology (NYSE: PBYI) has nearly tripled in value Wednesday on positive trial data for its lead breast cancer drug, while one analyst said the company is a likely takeover target. After the close Tuesday, the company said a Phase III clinical trial of its neratinib breast cancer drug...
-
UPDATE: UBS Upgrades Seattle Genetics
Wednesday, July 9, 2014 - 11:44am | 107Read More...In a research note released Wednesday, UBS analyst Matthew Roden upgraded Seattle Genetics (NASDAQ: SGEN) from Neutral to Buy and maintained a $48.00 price target. Roden said the firm made the upgrade based on two primary reasons: the stock's underperformance this year due to increased...
-
UPDATE: UBS Investment Research Raises PT on Incyte Following 2Q13 Results
Friday, August 2, 2013 - 11:09am | 158Read More...In a report published Friday, UBS Investment Research analyst Matthew Roden reiterated a Buy rating on Incyte (NASDAQ: INCY), and raised the price target from $27.00 to $28.00. In the report, UBS Investment Research noted, “We've felt all year that Incyte has had the data it needs to improve...
